Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

BRCA1 regulation of Osteoprotegerin: A Novel Biomarker for BRCA1-Associated Breast Cancer

FY 2018-19

Summary
Breast cancer is the most common form of cancer in women, affecting approximately 1 in 8 women in Canada. A subset of the female population faces an even greater risk of developing breast cancer due to a mutation in the BRCA1 gene. This mutation drastically increases their risk of developing breast cancer to about 70%. It is the women with this mutation that I am focusing on for my Master’s research. Currently, the most effective prevention strategy for mutation carriers is a bilateral mastectomy, however, the invasive nature of the surgery means many women instead choose to undergo more frequent screening to identify possible breast cancers at an earlier and more treatable stage. Despite having known about the risks associated with BRCA1 gene mutations for over two decades, there have been few advancements in our breast cancer prevention strategies. Thus, new avenues for preventing BRCA1-associated breast cancers must be explored. Recently, the protein Osteoprotegerin (OPG) has been implicated in the biological pathway contributing to the development of breast cancer in BRCA1-mutation carriers. Clinical studies reported low blood levels of OPG in BRCA1-mutation carriers, whereas women with higher levels of OPG were reported to be at a much lower risk of developing BRCA-associated breast cancer. This suggests that OPG may be protective against breast cancer. What remains unknown is how BRCA1 is regulating circulating OPG, and it is this question that I hope to answer through my Master’s research. Our research aims to understand OPG regulation in BRCA1 mutation carriers in the hopes of identifying new targets for drug interventions that increase or mimic the anti-cancer activity of OPG and therefore reduce the incidence of breast cancer in these high-risk women.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406386
Name
Uzelac Aleksandra
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
BRCA1 regulation of Osteoprotegerin: A Novel Biomarker for BRCA1-Associated Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarkers; Brca1; Breast Cancer Prevention; Hereditary Breast Cancer; Osteoprotegerin; Pharmacology
Abstract
Breast cancer is the most common form of cancer in women, affecting approximately 1 in 8 women in Canada. A subset of the female population faces an even greater risk of developing breast cancer due to a mutation in the BRCA1 gene. This mutation drastically increases their risk of developing breast cancer to about 70%. It is the women with this mutation that I am focusing on for my Master’s research. Currently, the most effective prevention strategy for mutation carriers is a bilateral mastectomy, however, the invasive nature of the surgery means many women instead choose to undergo more frequent screening to identify possible breast cancers at an earlier and more treatable stage. Despite having known about the risks associated with BRCA1 gene mutations for over two decades, there have been few advancements in our breast cancer prevention strategies. Thus, new avenues for preventing BRCA1-associated breast cancers must be explored. Recently, the protein Osteoprotegerin (OPG) has been implicated in the biological pathway contributing to the development of breast cancer in BRCA1-mutation carriers. Clinical studies reported low blood levels of OPG in BRCA1-mutation carriers, whereas women with higher levels of OPG were reported to be at a much lower risk of developing BRCA-associated breast cancer. This suggests that OPG may be protective against breast cancer. What remains unknown is how BRCA1 is regulating circulating OPG, and it is this question that I hope to answer through my Master’s research. Our research aims to understand OPG regulation in BRCA1 mutation carriers in the hopes of identifying new targets for drug interventions that increase or mimic the anti-cancer activity of OPG and therefore reduce the incidence of breast cancer in these high-risk women.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Uzelac, Aleksandra
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~